An oral vaccine against candidiasis generated by a yeast molecular display system
An oral vaccine against candidiasis generated by a yeast molecular display system
复制标题
DOI：
10.1111/2049-632x.12068
复制
发表时间：
2013-12-01
影响因子：
3.3
通讯作者：
Ueda, Mitsuyoshi
中科院分区：
文献类型：
--
作者：
Shibasaki, Seiji;Aoki, Wataru;Ueda, Mitsuyoshi
白色念珠菌的烯醇化酶 1 (Eno1p) 是一种免疫显性抗原。然而，制备注射疫苗的常规技术需要纯化抗原蛋白并制备佐剂。为了开发一种新型的针对念珠菌病的口服疫苗，我们生成了在其表面展示 Eno1p 抗原的酿酒酵母细胞。口服工程酿酒酵母细胞可延长随后接受白色念珠菌攻击的小鼠的存活率。鉴于使用分子展示技术生产的疫苗无需进行蛋白质纯化，这种口服疫苗为预防一系列传染病提供了一种有希望的替代传统疫苗和注射疫苗的方法。本文介绍了针对白色念珠菌烯醇化酶 1 (Eno1p) 的口服疫苗的开发。使用酿酒酵母细胞表面工程所采用的方法是原创的，也是现代口服疫苗生产方式的一个适当例子。
Enolase 1 (Eno1p) of Candida albicans is an immunodominant antigen. However, conventional technologies for preparing an injectable vaccine require purification of the antigenic protein and preparation of an adjuvant. To develop a novel type of oral vaccine against candidiasis, we generated Saccharomyces cerevisiae cells that display the Eno1p antigen on their surfaces. Oral delivery of the engineered S.cerevisiae cells prolonged survival rate of mice that were subsequently challenged with C.albicans. Given that a vaccine produced using molecular display technology avoids the need for protein purification, this oral vaccine offers a promising alternative to the use of conventional and injectable vaccines for preventing a range of infectious diseases.This paper deals with the development of an oral vaccine against Enolase 1 (Eno1p) of Candida albicans. The approach taken by using cell surface engineering of Saccharomyces cerevisiae is original and a proper example of how modern oral vaccines can be produced.